Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Albumin-bound paclitaxel (nab-PTX), a novel paclitaxel preparation, has been found to successfully blocks tumor progression in breast and lung cancer. However, at the same time of as clinical application, neurotoxicity caused by nab-PTX has become the main factor limiting the clinical application of nab-PTX, which seriously affects the quality of life of patients and increases their psychological or financial burden. In clinical applications, JHGWD combined with bloodletting therapy at the end of the extremities has a positive effect on neurotoxic symptoms such as numbness, pain, and weakness of the hands and feet caused by nab-PTX. In a single-arm experiment, it was also found that the immediate effective rate of exsanguination therapy was as high as 70%, and when combined with oral Chinese medicine treatment, it further improved the efficacy. Therefore, a randomized controlled trial (RCT) was designed to further evaluate the efficacy and safety of this treatment.
Methods: This RCT will be conducted at the Shanxi Provincial Hospital of Traditional Chinese Medicine. A total of 120 patients with Nab-PTX chemotherapy-induced neurotoxicity will be recruited. Treatment groups will be categorized into herbs alone group, bloodletting treatment alone group, and herbs combined with bloodletting group. Blank control was used. The primary outcome will be the EORTC QLQ-CIPN20 scale of the included patients, and the secondary outcomes will include EMG, peripheral neurotoxicity symptom score, NCI-CTCAE5.0 peripheral neurotoxicity grade, and WHO anti-tumor drug peripheral neurotoxicity grade. Adverse reactions will be recorded throughout the process. All data in this RCT will be analyzed by SPSS 26.0 software.
Discussion: The results of this RCT will contribute to treating PIPN, relieving the neurotoxic symptoms, and improving the quality of life of patients. Finally, the RCT results will be published in a relevant academic journal on completion of the trial.
Trial Registration: ChiCTR2200060217(May22,2022).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794297 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000032252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Tidsskr Nor Laegeforen
September 2025
Nevrologisk avdeling, Haukeland universitetssjukehus, og, Klinisk institutt 1, Universitetet i Bergen.
Immune-mediated toxicity from the use of immune checkpoint inhibitors is very common and can affect both the peripheral and central nervous systems. Given the potentially serious side effects, clinicians must maintain a high level of vigilance. The aim of this clinical review is to describe neurotoxic complications associated with the use of immune checkpoint inhibitors in cancer treatment.
View Article and Find Full Text PDFA Brazilian Minamata disease? Neurologists must be aware of mercury exposure and intoxication.
Arq Neuropsiquiatr
September 2025
Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém PR, Brazil.
Mercury intoxication poses a significant challenge and growing threat to public health, particularly in the Amazon region. Despite a known history of neurological damage, as evidenced by Japan's Minamata disease, mercury intoxication remains underdiagnosed in Brazil. This review underscores the need for increased clinical awareness among neurologists, as mercury exposure has been linked to over 250 neurological symptoms, including cognitive impairment, cerebellar ataxia, peripheral neuropathy, and psychiatric disturbances.
View Article and Find Full Text PDFImpact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors.
Cancer Med
September 2025
Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Background: Cisplatin is a commonly used chemotherapeutic across numerous cancer types that can cause neurotoxicities in patients, including peripheral sensory neuropathy, tinnitus, hearing loss, and vertigo.
Objective: We aimed to evaluate, for the first time, how genetic ancestry impacts cisplatin-induced neurotoxicities and if disparities are related to population differences in allele frequency.
Methods: In a cohort of cisplatin-treated testicular cancer survivors, relationships between genetic ancestry and neurotoxicities, medications, and lifestyle factors were assessed using logistic regression and Kruskal-Wallis tests and multiple pairwise comparisons using the Wilcoxon rank-sum test (Benjamini-Hochberg adjustment).
Corneal nerve loss associated with nitrous oxide neurotoxicity.
Clin Toxicol (Phila)
September 2025
School of Clinical Medicine, UNSW Sydney, Sydney, Australia.
Introduction: Nitrous oxide is an inhaled anaesthetic used recreationally that is neurotoxic. Corneal nerve parameters were assessed in patients with nitrous oxide toxicity.
Methods: Four individuals underwent clinical, electrophysiological and corneal confocal microscopy assessment.
Contribution of S1pr1-featured astrocyte subpopulation to cisplatin-induced neuropathic pain in male mice.
Pain
September 2025
Department of Pharmacology and Physiology, The Institute for Translational Neuroscience, Saint Louis University School of Medicine, St. Louis, MO, United States.
Chemotherapy-induced peripheral neuropathy accompanied by neuropathic pain (CIPN) is a major neurotoxicity of cisplatin, a platinum-based drug widely used for lung, ovarian, and testicular cancer treatment. Chemotherapy-induced peripheral neuropathy accompanied by neuropathic pain causes drug discontinuation and severely affects life quality with no FDA-approved interventions. We previously reported that platinum-based drugs increase levels of sphingosine 1-phosphate (S1P) in the spinal cord and drive CIPN through activating the S1P receptor subtype 1 (S1PR1).
View Article and Find Full Text PDF